Zydus Wellness will continue to do well: Avinnash Gorakssakar

In a chat with ET Now, Avinnash Gorakssakar, Head of Research, Miintdirect.com, shares his views on the pharma sector.

ET Now: You used to track some of these MNC pharma companies as well. There is a Pfizer which is active. Zydus is up 14 per cent as well. Any thoughts here?

Avinnash Gorakssakar: In case of Zydus Wellness, they continue to be market leaders in the sugar-free kind of segment. The kind of ROE this company has generated over the last couple of years, going forward also in terms of dividends and in terms of ROE, this is going to continue. So despite these kind of expensive valuations, these stocks would continue to do well because the fear of any equity dilution is not there and they have been extremely investor friendly to the shareholders. So I would say that on any decline, these are good portfolio picks which could actually generate good wealth for investors.